Human Fibrinogen Concentrate
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fibrinogen Deficiency
Conditions
Fibrinogen Deficiency
Trial Timeline
Jul 1, 2007 → May 1, 2008
NCT ID
NCT00496262About Human Fibrinogen Concentrate
Human Fibrinogen Concentrate is a phase 2 stage product being developed by CSL for Fibrinogen Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00496262. Target conditions include Fibrinogen Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01283321 | Phase 2 | Terminated |
| NCT00496262 | Phase 2 | Completed |
Competing Products
9 competing products in Fibrinogen Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fibrinogen Concentrate, Human (FCH) + Cryoprecipitate | CSL | Phase 3 | 76 |
| Haemocomplettan® P + Human albumin (Placebo) | CSL | Phase 2/3 | 64 |
| FCH | CSL | Pre-clinical | 22 |
| CSL511 Fibrinogen concentrate (human) + Cryoprecipitate | CSL | Phase 3 | 76 |
| BT524 (Part I) + BT524 (Part II) | ICON plc. | Phase 3 | 74 |
| FIB Grifols | Grifols | Phase 3 | 74 |
| Human Plasma-Derived Fibrinogen Concentrate | Grifols | Phase 1/2 | 38 |
| Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor | Cerus | Pre-clinical | 15 |
| Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate | Cerus | Approved | 77 |